Data / Form D filings / Chase Therapeutics Corp
Chase Therapeutics Corp: Form D filings
Chase Therapeutics Corp, a pharmaceuticals company in Washington, DC, filed 2 Form D notices with the SEC between 2017 and 2018. The latest, on August 28, 2018, reports $4 million sold of a $4 million offering to 3 investors.
Find out what Chase Therapeutics Corp does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1825 K STREET NW, SUITE 510, Washington, DC, 20006
- Phone
- (202) 223-7002
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2017
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1723805
The full lists. Form D filings in District of Columbia: 247 rows, $12.35, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 28, 2018 | New notice | $4,000,000 | $4,000,000 | $0 | 3 | Aug 21, 2018 | sec.gov |
| Nov 29, 2017 | New notice | $1,300,000 | $1,300,000 | $0 | 1 | Nov 17, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Richard P. Dulik | Executive Officer | |
| Kathleen N. Clarence-Smith | Director | |
| Karoly P. Nikolich | Director | |
| John P. Reher | Director | |
| Thomas N. Chase | Executive Officer, Director |
Every Form D from the week of Aug 27, 2018 · All recent filings in District of Columbia · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Chase Therapeutics Corp reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.